Collegium Pharmaceutical, Inc. COLL Payment for Contingent Consideration Liability, Financing Activities
Payment for Contingent Consideration Liability, Financing Activities at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s payment for contingent consideration liability, financing activities.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s payment for contingent consideration liability, financing activities?
- Collegium Pharmaceutical, Inc. (COLL) reported payment for contingent consideration liability, financing activities of $0 in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s payment for contingent consideration liability, financing activities changed year-over-year?
- Collegium Pharmaceutical, Inc.'s payment for contingent consideration liability, financing activities decreased by 100.0% year-over-year, from $555K to $0.